1. Home
  2. PRAX vs MTUS Comparison

PRAX vs MTUS Comparison

Compare PRAX & MTUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • MTUS
  • Stock Information
  • Founded
  • PRAX 2015
  • MTUS 1899
  • Country
  • PRAX United States
  • MTUS United States
  • Employees
  • PRAX N/A
  • MTUS 1880
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • MTUS
  • Sector
  • PRAX Health Care
  • MTUS
  • Exchange
  • PRAX Nasdaq
  • MTUS NYSE
  • Market Cap
  • PRAX 599.7M
  • MTUS 546.3M
  • IPO Year
  • PRAX 2020
  • MTUS N/A
  • Fundamental
  • Price
  • PRAX $38.55
  • MTUS $12.63
  • Analyst Decision
  • PRAX Strong Buy
  • MTUS
  • Analyst Count
  • PRAX 10
  • MTUS 0
  • Target Price
  • PRAX $116.50
  • MTUS N/A
  • AVG Volume (30 Days)
  • PRAX 320.6K
  • MTUS 431.7K
  • Earning Date
  • PRAX 05-02-2025
  • MTUS 05-08-2025
  • Dividend Yield
  • PRAX N/A
  • MTUS N/A
  • EPS Growth
  • PRAX N/A
  • MTUS N/A
  • EPS
  • PRAX N/A
  • MTUS N/A
  • Revenue
  • PRAX $8,122,000.00
  • MTUS $1,042,900,000.00
  • Revenue This Year
  • PRAX N/A
  • MTUS $8.67
  • Revenue Next Year
  • PRAX N/A
  • MTUS $9.17
  • P/E Ratio
  • PRAX N/A
  • MTUS N/A
  • Revenue Growth
  • PRAX 270.02
  • MTUS N/A
  • 52 Week Low
  • PRAX $26.70
  • MTUS $10.78
  • 52 Week High
  • PRAX $91.83
  • MTUS $24.28
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 53.72
  • MTUS 47.03
  • Support Level
  • PRAX $35.21
  • MTUS $12.16
  • Resistance Level
  • PRAX $38.90
  • MTUS $13.39
  • Average True Range (ATR)
  • PRAX 2.09
  • MTUS 0.49
  • MACD
  • PRAX 0.07
  • MTUS -0.03
  • Stochastic Oscillator
  • PRAX 69.58
  • MTUS 32.21

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About MTUS METALLUS INC

Metallus Inc is an America-based manufacturer of alloy steel, as well as carbon and micro-alloy steel. The portfolio of the company includes special bar quality steel, seamless mechanical tubes, and value-add solutions, such as precision steel components. The company also supplies machining and thermal treatment services and manages raw material recycling programs that work as a feeder system for its melt operations. The company's products and services are used in the following sectors: oil and gas; automotive; industrial equipment; mining; construction; rail; aerospace and defense; heavy truck; agriculture and power generation. Geographically, the company mainly serves customers in the United States.

Share on Social Networks: